ネフローゼ症候群におけるリンパ球除去療法(<特集>腎疾患とアフェレシス-最近の知見-)

概要

論文の詳細を見る
A considerable permeability factor (or factors) derived from lymphocytes would have a crucial role in nephritic syndrome, especially for minimal change nephritic syndrome and focal segmental glomerulosclerosis. This finding implies the potential clinical application of lympocytapheresis (LCAP) for these diseases. We reported a series of effective cases of LCAP for nephritic syndrome. LCAP was performed 2 times in 2 consecutive weeks in 6 patients with primary nephritic syndrome using Cellsorba (Asahi Medical Co., Osaka, Japan). Four patients showed a significant decrease of proteinuria after LCAP and the following immunosuppressive therapy. The other 2 patients had no response to LCAP or the following immunosuppressive therapy and suffered from end-stage renal failure or death from pneumonia. These results suggested that LCAP might have a beneficial effect on the treatment of nephritic syndrome, despite varying responses to LCAP and the following immunosuppressive therapy. Further studies will be needed to be established the effectiveness of LCAP for nephritic syndrome more in depth.
2011-05-31